Adenovirus-based viral vector vaccine technology
This technology enabled us to translate our globally innovative Ebola virus vaccine from a concept to an approved product in only three years. Our adenovirus-based vector technology is also applied to our TB Booster and other vaccine candidates.
Our conjugation technology and conjugation process know-how enable us to manufacture a wide range of conjugate vaccines. In addition to commonly used DT and TT carrier proteins, we have a number of carrier proteins including CRM197, which is produced by our proprietary high-yield bacterial strain and used in our MCV candidates. Our wide range of carrier proteins allows us to develop better multi-valent conjugate and combination vaccines, which distinguishes us from many of our competitors in China. In particular, our potential China best-in-class PCV13i employs a combination of different carrier proteins and is currently ready for CTA.
Protein structure design and recombinant technology
We have used protein structure design technology to design pneumococcal protein antigens. In addition, we have developed novel recombinant strains to produce a new generation pertussis vaccine. We also developed a proprietary cell line to be used for viral vector production.
Our culture media formulations are free from animal components, and our final product formulations are free from undesired phenol and preservatives. Such characteristics ensure consistent product quality and reduce potential risks of side effects.
Copyright © ( 2017) CanSino Biologics Inc
For the record: 津ICP备14006666号-2